Key Highlights
- Shares trading down 1.28% to $2.32 in today's session.
- Trading Volume reached 21.95 thousand shares.
- The company reported an EPS of negative $8.99.
- Revised enrollment criteria have been approved at nine of eleven active trial sites.
Enrollment Criteria Widened to Speed Up Trial
Aclarion, Inc. (NASDAQ:ACON), a healthcare technology company focused on diagnosing chronic low back pain, said it broadened the enrollment criteria for its pivotal CLARITY trial after enrollment lagged under the original, more narrowly defined criteria. The revised criteria have now been approved at nine of the company's eleven active trial sites, with two more using them for screening ahead of local approval.
Timeline Update Expected by Year-End
The company said it will provide an update on enrollment levels and the anticipated timeline for its initial trial readout by year-end. Despite the changes, the company maintained that the overall length of the trial is not expected to be extended as a result of the adjustment.
Shares Dip Slightly Following the Update
Shares slipped modestly today, with an EPS of negative $8.99 reflecting the company's pre-commercial stage as it continues to generate evidence for its Nociscan diagnostic platform. The stock's 52-week range of $1.95 to $12.03 reflects its Volatility as a small, thinly traded name.
Outlook: Faster Enrollment Could Support Trial Timeline
With broader criteria now in place across most sites, the company expects meaningful acceleration in patient enrollment going forward. The upcoming year-end update may give investors clearer visibility into when the trial's initial data readout could arrive.
FAQs
Q: Why did Aclarion stock fall today?
A: Shares fell 1.28% after the company announced it had broadened enrollment criteria for its pivotal CLARITY trial following slower than expected enrollment.
Q: Why were the criteria changed?
A: The original criteria were narrowly defined for scientific rigor but excluded a large share of real-world chronic low back pain patients, slowing enrollment.
Q: Will the trial take longer because of this change?
A: The company said it does not expect the overall length of the trial to be extended as a result of the revised criteria.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.